ReviewTherapeutic advances in psychopharmacology2024
Neuroimaging features of cognitive impairments in schizophrenia and major depressive disorder.
Review in Therapeutic advances in psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Transcranial direct current stimulation and cognitive training in the treatment of cognitive deficit in schizophrenia: a randomized controlled trial.BMC psychiatry · 2026Trial
- Loneliness, Genetic Susceptibility, Brain Structure, and the Risk of Schizophrenia: A Large Prospective Study.Schizophrenia bulletin · 2026Article
- The association between spatiotemporal coupling of default mode network and behaviors is specifically modulated by peripheral inflammation in major depressive disorder.BMC psychiatry · 2026Article
- Personality and Psychotic-Like Features in Post-Traumatic Stress Disorder With Severe Depression: An Minnesota Multiphasic Personality Inventory-2 Schizophrenia Scale Analysis.Psychiatry investigation · 2026Article
- Cognitive and emotional effects of bilateral prefrontal anodal tDCS and high-frequency tRNS in schizophrenia: a randomized sham-controlled study.Schizophrenia (Heidelberg, Germany) · 2026Article
- Cognitive impairment based on computerized testing among patients with major depressive disorder after remission.Frontiers in human neuroscience · 2026Article
- Article
- Dynamic Brain Age Modeling Identifies Network-Specific Cognitive Deficits in Schizophrenia.Research square · 2025Article
- Disentangling shared and unique brain functional changes associated with clinical severity and cognitive phenotypes in schizophrenia via deep learning.Communications biology · 2025Article
- Functional Brain Age Acceleration from Dynamic and Static Connectivity Predicts Working Memory and Attention Deficits in Schizophrenia.medRxiv : the preprint server for health sciences · 2025Article
- Differential patterns of executive dysfunction across depressive phenotype in schizophrenia and major depressive disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation.International journal of molecular sciences · 2025Review
- The association between depressive symptoms and limitations in disability domains among US adults.Journal of mood and anxiety disorders · 2025Article
- Abnormal brain network reconfiguration in neuropsychiatric disorders across cognitive decline, Depression, and Schizophrenia.PloS one · 2025Article
- Static and dynamic brain functional connectivity patterns in patients with unilateral moderate-to-severe asymptomatic carotid stenosis.Frontiers in aging neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive dysfunctions are one of the key symptoms of schizophrenia (SZ) and major depressive disorder (MDD), which exist not only during the onset of diseases but also before the onset, even after the remission of psychiatric symptoms. With the development of neuroimaging techniques, these non-invasive approaches provide valuable insights into the underlying pathogenesis of psychiatric disorders and information of cognitive remediation interventions. This review synthesizes existing neuroimaging studies to examine domains of cognitive impairment, particularly processing speed, memory, attention, and executive function in SZ and MDD patients. First, white matter (WM) abnormalities are observed in processing speed deficits in both SZ and MDD, with distinct neuroimaging findings highlighting WM connectivity abnormalities in SZ and WM hyperintensity caused by small vessel disease in MDD. Additionally, the abnormal functions of prefrontal cortex and medial temporal lobe are found in both SZ and MDD patients during various memory tasks, while aberrant amygdala activity potentially contributes to a preference to negative memories in MDD. Furthermore, impaired large-scale networks including frontoparietal network, dorsal attention network, and ventral attention network are related to attention deficits, both in SZ and MDD patients. Finally, abnormal activity and volume of the dorsolateral prefrontal cortex (DLPFC) and abnormal functional connections between the DLPFC and the cerebellum are associated with executive dysfunction in both SZ and MDD. Despite these insights, longitudinal neuroimaging studies are lacking, impeding a comprehensive understanding of cognitive changes and the development of early intervention strategies for SZ and MDD. Addressing this gap is critical for advancing our knowledge and improving patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.